secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001213900-26-037501
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports early LYMPHIR launch traction; 83% of target accounts in formulary review
--------------------------------------------------------------------------------

- 83% of target accounts have added or are actively progressing LYMPHIR through formulary review.
- Market access covering ~80% of covered lives via ~135 health plans; no reimbursement denials reported.
- Initial accounts placing repeat orders; sequential growth in orders since launch.
- Investigator-led studies: LYMPHIR prior to CAR-T in DLBCL (U Minnesota) and combo with pembrolizumab in solid tumors (UPMC).
- Field team onboarding underway; international expansion with distribution agreements in Europe/Middle East.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026037501/0001213900-26-037501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026037501/ea0284321-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-037501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer